![]() |
|
|
Vol. 281, Issue 1, 582-588, 1997
Los Andes University, Department of Physiology, School of Medicine,
Mérida, Venezuela
The effects of i.p. clozapine [0 (n = 6), 5 (n = 5), 10 (n = 5), 20 (n = 9) and 40 (n = 5) mg/kg]
on acetylcholine (ACh) release in the prefrontal cortex (PFC), nucleus
accumbens (NAC) and striatum (STR) were studied by simultaneous triple
microdialysis in freely moving rats. Clozapine dose-responsively
increased extracellular ACh in the studied areas. The effect was larger
in the PFC. Comparisons of the slopes of the regression equations
showed differences between the effects in PFC and nucleus accumbens
(t = 4.29; df = 56; P < .001) and PFC
and STR (t = 4.56), but not between nucleus
accumbens and STR. These differential actions were not artifacts of the simultaneous perfusion because clozapine (20 mg/kg) increased ACh
levels during single microdialysis of the PFC (353 ± 72%; n = 5) or STR (168 ± 24%;
n = 5), in the same proportion as the respective
increases in those areas during the simultaneous triple microdialysis
(PFC = 330 ± 41%; STR = 144 ± 18%;
n = 9). Local infusion of tetrodotoxin (10 µM)
reduced ACh in the areas studied to about 30% of the mean baselines,
confirming the neuronal origin of this neurotransmitter. Extrapolation
of these results to humans suggests that adequate levels of cholinergic
activity in the PFC are required for mental health, and that a similar
ACh release in the human PFC by clozapine could be therapeutic. The low
impact on striatal ACh could explain the lack of extrapyramidal
symptoms by clozapine.